secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008300
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam provides pipeline update; cash ~$729M; EMA decision expected 2H26
------------------------------------------------------------------------------

- Unaudited cash, cash equivalents and marketable securities ~$729M as of Dec 31, 2025.
- EMA approval decision for obicetrapib monotherapy and FDC expected in 2H26.
- PREVAIL CVOT overall MACE event rate tracking in line with BROADWAY; fully enrolled with >9,500 patients.
- First patient enrolled in RUBENS Phase 3 trial for metabolic syndrome; topline data expected year-end 2026.
- Plans to initiate first dedicated Alzheimer's trial in 2026 based on positive biomarker data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/0001193125-26-008300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526008300/nams-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer